Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GF-4001
- Development stage
- Preclinical
- Lead developer
- GenFlow Biosciences
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous
01
Overview
GF-4001 is a non-human (veterinary) version of the anti-aging gene therapy GF-1002, developed by Genflow Biosciences. It is designed for use in dogs and utilizes an adeno-associated viral (AAV) vector to deliver a variant of the Sirtuin 6 (SIRT6) gene found in centenarians. The therapy aims to improve DNA maintenance and delay age-related diseases by providing additional copies of this longevity-associated gene. Unlike human-targeted versions, GF-4001 is specifically formulated for veterinary applications[3][4].
02
Targets
SIRT6 (Sirtuin 6)
Beyond the preview
Go deeper on GF-4001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GF-4001.